IN2012DN00167A - - Google Patents

Info

Publication number
IN2012DN00167A
IN2012DN00167A IN167DEN2012A IN2012DN00167A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A IN 167DEN2012 A IN167DEN2012 A IN 167DEN2012A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A
Authority
IN
India
Prior art keywords
treatment
compositions
concerned
methods
multiple sclerosis
Prior art date
Application number
Inventor
B Gelder Frank
Alison Webster Gillian
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of IN2012DN00167A publication Critical patent/IN2012DN00167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Photographic Developing Apparatuses (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is concerned with novel compositions and methods for the treatment of Multiple Sclerosis (MS) and in particular with immunostimulatory compositions comprising muramyl dipeptide microparticles in the treatment of MS.
IN167DEN2012 2009-06-16 2010-06-16 IN2012DN00167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IN2012DN00167A true IN2012DN00167A (en) 2015-04-17

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
IN167DEN2012 IN2012DN00167A (en) 2009-06-16 2010-06-16

Country Status (21)

Country Link
US (1) US8389479B2 (en)
EP (1) EP2442832B1 (en)
JP (1) JP5646617B2 (en)
CN (1) CN102458476B (en)
AU (1) AU2010260585B2 (en)
BR (1) BRPI1009606A2 (en)
CA (1) CA2688766C (en)
CY (1) CY1115714T1 (en)
DK (1) DK2442832T3 (en)
ES (1) ES2521565T3 (en)
HK (1) HK1167101A1 (en)
HR (1) HRP20141035T1 (en)
IL (1) IL216993A (en)
IN (1) IN2012DN00167A (en)
MX (1) MX2011013661A (en)
NZ (1) NZ577731A (en)
PL (1) PL2442832T3 (en)
PT (1) PT2442832E (en)
SI (1) SI2442832T1 (en)
SM (1) SMT201400165B (en)
WO (1) WO2010147484A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906312A2 (en) * 2008-04-01 2016-07-05 Innate Therapeutics Ltd "use of dpm / dna microparticle for compound, composition and vaccine manufacturing"
RS60565B1 (en) * 2010-10-25 2020-08-31 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
UY35790A (en) * 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
AU2016202146A1 (en) * 2015-10-06 2017-04-20 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CA3099946A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939835A4 (en) * 1996-10-10 2004-10-27 Probe Internat Compositions and methods for treating viral infections
US20080193440A1 (en) * 2004-07-01 2008-08-14 Kobenhavns Universitet Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
JP2008251608A (en) 2007-03-29 2008-10-16 Casio Comput Co Ltd Semiconductor device and manufacturing process of the same
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Also Published As

Publication number Publication date
AU2010260585A1 (en) 2012-01-19
JP2012530132A (en) 2012-11-29
CY1115714T1 (en) 2017-01-25
CA2688766C (en) 2015-06-30
HRP20141035T1 (en) 2014-12-19
PT2442832E (en) 2014-11-11
DK2442832T3 (en) 2014-11-10
AU2010260585B2 (en) 2013-02-21
MX2011013661A (en) 2012-05-22
BRPI1009606A2 (en) 2016-10-11
EP2442832A4 (en) 2013-07-03
SMT201400165B (en) 2015-01-15
SI2442832T1 (en) 2014-12-31
IL216993A0 (en) 2012-02-29
JP5646617B2 (en) 2014-12-24
ES2521565T3 (en) 2014-11-12
US20100317589A1 (en) 2010-12-16
WO2010147484A8 (en) 2012-07-19
CN102458476B (en) 2014-08-20
HK1167101A1 (en) 2013-02-01
EP2442832A1 (en) 2012-04-25
EP2442832B1 (en) 2014-08-06
IL216993A (en) 2016-03-31
PL2442832T3 (en) 2015-01-30
WO2010147484A1 (en) 2010-12-23
CA2688766A1 (en) 2010-12-16
US8389479B2 (en) 2013-03-05
AU2010260585A8 (en) 2012-06-14
CN102458476A (en) 2012-05-16
NZ577731A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
IN2012DN00167A (en)
IL272817A (en) Novel compositions and methods for the treatment of immune related diseases
MX2012006549A (en) Compositions and methods comprising protease variants.
PH12014500053A1 (en) Proteasome inhibitors
EP2464724A4 (en) Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
IN2012DN03883A (en)
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MX2011009690A (en) Methods and compositions for cell-proliferation-related disorders.
IN2012DN00971A (en)
JO2860B1 (en) Vinyl indazolyl compounds
MX2011008179A (en) Peptides for vaccine.
MX336742B (en) Fatty acid amide hydrolase inhibitors.
EP2566485A4 (en) Immunostimulatory compositions and methods of use thereof
EP2597949A4 (en) Sub-micron compositions
EP2445873A4 (en) Protease inhibitors, compositions and methods of use
MY161460A (en) Elastomeric dental floss
MX2011010046A (en) Diaminopteridine derivatives.
MX2012012509A (en) Tapentadol for use in the treatment of irritable bowel syndrome.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
MY180594A (en) Proteasome inhibitors
GEP20146006B (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide
UA42373U (en) Use of taurin and jacton as antioxidant and genome protector